Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jul;5(7):745-55.
doi: 10.1517/17425250902973711.

Pharmacogenomics of platinum-based chemotherapy in NSCLC

Michelle A T Hildebrandt  1 , Jian Gu, Xifeng Wu
Affiliations
Review

Pharmacogenomics of platinum-based chemotherapy in NSCLC

Michelle A T Hildebrandt et al. Expert Opin Drug Metab Toxicol. 2009 Jul.

Abstract

NSCLC is the leading cause of cancer-related death in the US. Patients with NSCLC are mostly treated with platinum-based chemotherapy, often in combination with radiation therapy. However, the development of chemo-resistance is a major hurdle limiting treatment success. In this review, we summarize the current understanding of the genetic factors modulating chemoresistance to platinum chemotherapeutics and their association with clinical outcomes for NSCLC patients. We focus on candidate pathways responsible for drug influx and efflux, metabolism and detoxification, DNA damage repair, and other downstream cellular processes that modulate the effect of platinum-based therapy. We also discuss the application of pathway-based polygenic and genome-wide approaches in identifying genetic factors involved in NSCLC clinical outcomes. Overall, current studies have shown that the effects of each individual polymorphism on clinical outcomes are modest suggesting that a more comprehensive approach that incorporates polygenetic, phenotypic, epidemiologic and clinical variables will be necessary to predict prognosis for NSCLC patients receiving platinum-based chemotherapeutics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Platinum drug action pathway.
Figure 2
Figure 2
Nucleotide excision repair (NER) of platinum-DNA adducts.
See this image and copyright information in PMC

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. - PubMed
    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. - PubMed
    1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379–392. - PubMed
    1. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer–report of a Canadian multicenter randomized trial. J Clin Oncol. 1988;6(4):633–641. - PubMed

    1. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–4625. •• Systematic study of supporting the advantage of including chemotherapy in the treatment of NSCLC.

Publication types

MeSH terms